Clinical Trials Logo

Neuritis clinical trials

View clinical trials related to Neuritis.

Filter by:

NCT ID: NCT00179478 Completed - Multiple Sclerosis Clinical Trials

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

CHAMPIONS10
Start date: February 2001
Phase: Phase 4
Study type: Interventional

The current study is an extension of the previous phase III CHAMPS study (see reference). This study was designed to determine if immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis continues to delay the development of further attacks and the development of neurological disability over a 10 year period of observation.

NCT ID: NCT00037115 Withdrawn - Multiple Sclerosis Clinical Trials

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Start date: May 2002
Phase: Phase 4
Study type: Interventional

The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along with the standard solumedrol treatment before beginning AVONEX® treatment.

NCT ID: NCT00000147 Active, not recruiting - Multiple Sclerosis Clinical Trials

Longitudinal Optic Neuritis Study (LONS)

Start date: July 1988
Phase: N/A
Study type: Interventional

To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.

NCT ID: NCT00000146 Active, not recruiting - Multiple Sclerosis Clinical Trials

Optic Neuritis Treatment Trial (ONTT)

Start date: July 1988
Phase: Phase 3
Study type: Interventional

To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.

NCT ID: NCT00000117 Completed - Optic Neuritis Clinical Trials

Intravenous Immunoglobulin Therapy in Optic Neuritis

Start date: August 1995
Phase: Phase 3
Study type: Interventional

To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can be confirmed, this would provide indirect evidence that IVIg may promote central nervous system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).